Last reviewed · How we verify
Maraviroc Pill
At a glance
| Generic name | Maraviroc Pill |
|---|---|
| Also known as | selzentry |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke (PHASE2)
- ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence (PHASE4)
- Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (PHASE3)
- Effect of Maraviroc on Endothelial Function in HIV-Infected Patients (PHASE3)
- Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I) (PHASE1)
- Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maraviroc Pill CI brief — competitive landscape report
- Maraviroc Pill updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI